Diabetic retinopathy was diagnosed in about one out of five patients with type 2 diabetes during the first year after diabetes diagnosis in UK general practices. Age, male sex, hyperglycaemia and hypertension were identified as risk factors of early retinopathy in type 2 diabetes (Diabetologia)
Diabetes News
Category: Ophthalmology
Automated diagnosis of diabetic retinopathy and glaucoma using fundus and OCT images
The accuracy for optical disk detection is found to be 97.75%. The proposed system therefore is accurate, reliable and robust and can be realized (Lipids in Health and Disease)
Hospitalized cardiovascular events in patients with diabetic macular edema
Event rates of MI or CVA were higher in patients with DME than in diabetes controls. This study is one of few with sufficient sample size to accurately estimate the relationship between DME and cardiovascular outcomes (BMC Ophthalmology)
A Microalbuminuria Threshold to Predict the Risk for the Development of Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients
These data suggest that an MA threshold can predict the risk for the development of DR in type 2 diabetes mellitus, although it is still within the traditionally established normal rang (PLoS ONE)
The anterior segment of the eye in diabetes
Primary care physicians and other allied health care professionals who are first in contact with patients are enjoined to familiarize themselves with the anterior segment features of diabetes mellitus and take necessary action when they are detected (Clinical Ophthalmology)
Enhanced Circulating Soluble LR11 in Patients with Diabetic Retinopathy
Serum sLR11 concentration may reflect the progression of PDR in patients with type 2 diabetes mellitus. sLR11, released from immature vascular cells and indicating the development of atherosclerosis, is expected to be a novel candidate biomarker indicating diabetic retinopathy in patients with T2D (American Journal of Ophthalmology)
Intravitreal bevacizumab for diabetic macular oedema
Results of a systematic review of randomised controlled trials of intravitreal bevacizumab for the treatment of diabetic macular oedema (Canadian Agency for Drugs and Technologies in Health)
RESTORE extension study in DME patients
New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients (Novartis)
- « Previous Page
- 1
- …
- 3
- 4
- 5